• BlossomHill Therapeutics will present BH-30236 preclinical and clinical data at the American Society of Hematology annual meeting on December 14, 2026.
• The findings support the oral CLK inhibitor’s mechanism of action, with consistent biological effects across preclinical studies and clinical testing.
• BH-30236 is in a Phase 1/1b trial for adults with relapsed or refractory acute myeloid leukemia or higher-risk myelodysplastic syndrome.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blossomhill Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040700PRIMZONEFULLFEED9869950) on November 04, 2026, and is solely responsible for the information contained therein.